Public Policy & Regulation Partner and Co-Leader of the firm's Healthcare & Life Sciences Team, Michael Werner was quoted by InsideHealthPolicy on whether the FDA is likely to receive a funding bump or continuing resolution (CR) in the next funding deal as the short-term spending bill ends Feb. 15, 2019. Mr. Werner is optimistic that Congress could pass a CR to fund the government at 2018 fiscal spending limits before the Feb. 15 deadline, but the CR would place greater restrictions on the FDA and how it spends its funding. Mr. Werner stated that the situation is not ideal, but it is preferable to another shutdown.
"I think that with every organization people want certainty and resolution," Mr. Werner said. "I think the more likely outcome will be a CR, and hopefully it will be a CR that goes through the whole year."
READ: FDA Experts: Will FDA Get Funding Bump Or CR In Next Funding Deal? (Subscription Required)